Cargando…

Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges

Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, Elizabeth, Pearlman, Jodie, Ruan, Travis, Manion, John, Waller, Matthew, Neely, Gregory G., Caron, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699962/
https://www.ncbi.nlm.nih.gov/pubmed/33233861
http://dx.doi.org/10.3390/cells9112517
_version_ 1783616169525116928
author Ford, Elizabeth
Pearlman, Jodie
Ruan, Travis
Manion, John
Waller, Matthew
Neely, Gregory G.
Caron, Leslie
author_facet Ford, Elizabeth
Pearlman, Jodie
Ruan, Travis
Manion, John
Waller, Matthew
Neely, Gregory G.
Caron, Leslie
author_sort Ford, Elizabeth
collection PubMed
description Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system.
format Online
Article
Text
id pubmed-7699962
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76999622020-11-29 Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges Ford, Elizabeth Pearlman, Jodie Ruan, Travis Manion, John Waller, Matthew Neely, Gregory G. Caron, Leslie Cells Review Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system. MDPI 2020-11-20 /pmc/articles/PMC7699962/ /pubmed/33233861 http://dx.doi.org/10.3390/cells9112517 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ford, Elizabeth
Pearlman, Jodie
Ruan, Travis
Manion, John
Waller, Matthew
Neely, Gregory G.
Caron, Leslie
Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title_full Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title_fullStr Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title_full_unstemmed Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title_short Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
title_sort human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699962/
https://www.ncbi.nlm.nih.gov/pubmed/33233861
http://dx.doi.org/10.3390/cells9112517
work_keys_str_mv AT fordelizabeth humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT pearlmanjodie humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT ruantravis humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT manionjohn humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT wallermatthew humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT neelygregoryg humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges
AT caronleslie humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges